BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1057 related articles for article (PubMed ID: 27816651)

  • 21. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
    Chevallier P; Labopin M; Socié G; Tabrizi R; Furst S; Lioure B; Guillaume T; Delaunay J; de La Tour RP; Vigouroux S; El-Cheikh J; Blaise D; Michallet M; Bilger K; Milpied N; Moreau P; Mohty M
    Haematologica; 2014 Sep; 99(9):1486-91. PubMed ID: 24951467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
    Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
    Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
    Kebriaei P; Madden T; Wang X; Thall PF; Ledesma C; de Lima M; Shpall EJ; Hosing C; Qazilbash M; Popat U; Alousi A; Nieto Y; Champlin RE; Jones RB; Andersson BS
    Bone Marrow Transplant; 2013 Jan; 48(1):26-31. PubMed ID: 22732703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
    Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
    Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant.
    Eroglu C; Pala C; Kaynar L; Yaray K; Aksozen MT; Bankir M; Zararsız G; Orhan O; Gündog M; Yıldız OG; Eser B; Cetin M; Unal A
    Leuk Lymphoma; 2013 Nov; 54(11):2474-9. PubMed ID: 23442062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
    Magenau J; Tobai H; Pawarode A; Braun T; Peres E; Reddy P; Kitko C; Choi S; Yanik G; Frame D; Harris A; Erba H; Kujawski L; Elenitoba-Johnson K; Sanks J; Jones D; Paczesny S; Ferrara J; Levine J; Mineishi S
    Blood; 2011 Oct; 118(15):4258-64. PubMed ID: 21841163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia.
    Tischer J; Stemmler HJ; Engel N; Hubmann M; Fritsch S; Prevalsek D; Schulz C; Zoellner AK; Bücklein V; Hill W; Ledderose G; Hausmann A
    Ann Hematol; 2013 Oct; 92(10):1379-88. PubMed ID: 23928857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
    Magenau J; Westervelt P; Khaled S; McGuirk J; Hari P; Eapen M; Becker PS; Parkin B; Braun T; Logan B; Wang H; Jagasia M; Rowley SD; Kim DD; Schechter T; Frey N; Scott B; Churay T; Lieland S; Forman S; Mineishi S
    Bone Marrow Transplant; 2017 Jan; 52(1):59-65. PubMed ID: 27427921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clofarabine/cyclophosphamide for debulking before stem cell transplantation.
    Rabitsch W; Böhm A; Bojic M; Schellongowski P; Wöhrer S; Sliwa T; Keil F; Worel N; Greinix H; Hauswirth A; Kalhs P; Jaeger U; Valent P; Sperr WR
    Eur J Clin Invest; 2014 Aug; 44(8):775-83. PubMed ID: 24942362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of allogeneic hematopoietic stem cell transplantation based on a total body irradiation conditioning treatment regimen for adult acute lymphocytic leukemia].
    Xiao QQ; Yu XL; Song XC; Hou YX; Deng L; Li WJ; Zhou F
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):249-256. PubMed ID: 38716596
    [No Abstract]   [Full Text] [Related]  

  • 33. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
    Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
    Speziali C; Daly A; Abuhaleeqa M; Nitta J; Abou Mourad Y; Seftel MD; Paulson K
    Leuk Lymphoma; 2019 Mar; 60(3):639-648. PubMed ID: 30160568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial.
    Peccatori J; Mastaglio S; Giglio F; Greco R; Crocchiolo R; Patriarca F; Forno B; Deola S; Assanelli A; Lupo Stanghellini MT; Marcatti M; Zecca M; Cortelazzo S; Fanin R; Fagioli F; Locatelli F; Ciceri F
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):316-322. PubMed ID: 31605823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.
    Soni S; Abdel-Azim H; McManus M; Nemecek E; Sposto R; Woolfrey A; Frangoul H
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1134-1141. PubMed ID: 28396162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.